Skip to main content

Advertisement

Table 3 Prognostic factors for disease-free survival: multivariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

  Model 1 (N = 570)   Model 2 (N = 575)  
  HR (95 % CI) p-valuea HR (95 % CI) p-valuea
Age
  < 35 1   1  
  ≥ 35 0.5 [0.1–2.3] 0.581 0.5 [0.1–.396] 0.440
SBR Grade
 1–2 1   NA  
 3 2.8 [1.4–5.4] 0.0027 NA  
Pathological tumor size
 pT1 1   1  
 pT2 0.9 [0.5–1.7] 0.897 0.9 [0.5–1.7] 0.916
 pT3-T4 0.4 [0.05–3.3] 0.431 0.4 [0.06–3.4] 0.447
PVI
 No 1   1  
 Yes 1.5 [0.8–3.0] 0.175 1.3 [0.7–2.6] 0.357
Hormone receptors
 Negative 1   NA  
 Positive 1.0 [0.5–2.2] 0.818 NA  
HER2
 Positive 1   NA  
 Negative 0.5 [0.2–1.4] 0.239 NA  
IHC subtypes
 Luminal A NA   1  
 Luminal B/HER2-negative NA   4.2 [1.9–9.1] 0.0002
 Luminal B/HER2-positive NA   0.7 [0.1–3.4] 0.721
 HER2 NA   1.76 [0.4–6.1] 0.38
 Triple-negative NA   2.5 [1.1–5.4] 0.0201
  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aWald test